An observational study in Carcinoma, Non-small-cell Lung Cancer and Lung Neoplasm, sponsored by Peking University People's Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Peking University People's Hospital · Observational
Among 101 studies in Carcinoma with a site in China — 37 open to participants now, 49 under way, 12 of them phase 3. Carcinoma · China.
Among the 101 studies in Carcinoma with a site in China, this one is the 7th largest by planned enrollment of the 19 observational ones, is one of 7 that started in 2019, is one of 19 observational ones, and was the 30th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
This study's planned enrollment of 400 is above the median of 165 across 129 observational studies indexed under Carcinoma.
Browse Carcinoma studies →37 of the 101 studies in Carcinoma with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →101 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 7 started in 2019.
Median enrollment 72 across the 82 interventional studies, 145 across the 19 observational. Of the 29 that completed or were terminated, 13 (45%) have results posted.
41 of 101 have an industry lead sponsor. The 10 most frequent:
Peking University People's Hospital is the lead sponsor of 609 studies on the registry; 247 are open to participants now.
Peking University People's Hospital has 9 studies filed under Carcinoma — fewer than ten, so there is no comparison to draw.
8 of the studies in Carcinoma with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT07453706Chinese University of Hong KongThe Application of Sentire Surgical System Plus Patient Side Single Arm in Robotic Colorectal Surgery | 2027-03 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT07400263Peking University People's HospitalEvaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors | 2027-06-30 |
| NCT05150691DualityBio Inc.A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | 2027-08 |
Among the 101 studies in Carcinoma with a site in China, from their registry updates:
Lung cancer is the leading cause of cancer-related death in China. This study will explore the applications of multiplex analysis of circulating tumor DNA biomarkers for diagnosis and surveillance of lung cancer patients
Non-small cell lung cancer (NSCLC) constitutes about 85% of all newly diagnosed cases of lung cancer and continues to be the leading cause of cancer-related deaths worldwide.Early diagnosis and monitoring tumor recurrence after surgery are still far from satisfying.
Circulating tumor DNA(ctDNA) detection has been proved to be feasible in early stage NSCLC in previous studies.Both genomic mutation and methylation a promising biomarker.Therefore,this study will perform multiplex detection of ctDNA,analysing mutations, methylation and other biomarkers,focusing on the early diagnosis and postoperative surveillance for NSCLC patients.
All patient are found nodules in pulmonary and prepare for surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The sensitivity and specificity of multiplex peripheral blood ctDNA biomarkers in the diagnosis of non-small cell lung cancer
Time frame: 12 months
Comparing the sensitivity and specificity of each peripheral blood biomarkers for the diagnosis of non-small cell lung cancer
Time frame: 12 months
The sensitivity and specificity of multiplex peripheral blood ctDNA biomarkers for tumor relapse detection
Time frame: 36 months
Lead time of tumor relapse detection by multiplex ctDNA biomarkers than radiographic approaches
Time frame: 36 months
Started Apr 2019 (actual). Primary completion is estimated for Jun 2020, 13 months after the start.
Of 50 non-industry observational studies under Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's planned 13 months is below that.
Counting every sponsor, half of 62 studies reached it within 49 months; a quarter within 29 and three quarters within 166.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University People's Hospital →